Partnerships for Countermeasures against Select Pathogens (R01) | Apply Online

Opportunity Summary:

Partnerships for Countermeasures against Select Pathogens (R01) (RFA-AI-16-034) is a discretionary NIH grant funding opportunity released by the U.S. Department of Health and Human Services through NIH (specifically NIAID-focused), aimed at accelerating the preclinical development of medical countermeasures for certain emerging infectious diseases and pathogens of interest to NIAID. The central idea is to move beyond basic discovery and into practical, milestone-driven development work that can advance a well-defined lead candidate toward a stage that is meaningfully closer to clinical testing or operational use. The FOA is oriented toward product-focused research rather than open-ended exploration, emphasizing deliverables, decision points, and measurable progress.

The projects targeted by this announcement are specifically preclinical development efforts for lead candidate countermeasures. These countermeasures can include therapeutics, vaccines (and enabling or related vaccine technologies), and diagnostics. In practice, that typically means work such as candidate optimization and selection, development of assays and performance benchmarks, demonstration of proof-of-concept in relevant models, evaluation of preliminary safety or toxicity where appropriate, refinement of formulations, stability and manufacturability considerations, development of diagnostic performance characteristics, and other studies that reduce risk and prepare a candidate for later-stage development. A key feature is that the research plan is expected to be structured around clear milestones, so applicants should propose objective criteria for success, go/no-go decision points, and a timeline that shows how the work will proceed in stages.

A defining requirement is the expectation of an active partnership with industry. Applications must demonstrate substantive investment by at least one industrial participant, signaling that the work is not only scientifically credible but also positioned for real-world development pathways. This is designed to strengthen translation and ensure that project planning accounts for practical product-development constraints such as scalability, regulatory strategy, quality systems, and downstream commercialization or deployment considerations. The industrial participant can be a for-profit entity and is expected to contribute in a meaningful way, such as funding, in-kind resources, development expertise, access to platforms, manufacturing capabilities, data packages, or other concrete commitments that materially increase the likelihood of success.

Another mandatory element is a Product Development Strategy attachment. This attachment is intended to make the application read more like a development plan than a standard academic research proposal. While the FOA text in your excerpt does not spell out the exact required contents, in this type of NIAID product-oriented program the strategy typically lays out the intended product concept and use case, target product profile or performance goals, development and manufacturing considerations, regulatory and nonclinical study approach, major risks and mitigation plans, and how the partnership will function to move the candidate forward. In other words, reviewers are looking for an integrated plan that connects scientific activities to a plausible path toward a usable countermeasure.

Eligibility is broad and includes many organization types that commonly participate in translational biomedical research. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other Native American tribal organizations; public housing authorities and Indian housing authorities; nonprofits both with and without 501(c)(3) status (when not institutions of higher education); for-profit organizations other than small businesses; small businesses; and other applicants as permitted by the FOA’s additional eligibility language. This breadth aligns with the program’s partnership intent, allowing academic centers, nonprofits, and commercial developers to assemble teams that match the needs of preclinical product development.

From an administrative standpoint, this opportunity uses the NIH R01 grant mechanism under the health-related funding activity category and is associated with CFDA numbers 93.855 and 93.856. The FOA was posted on March 29, 2016, with an original and current closing date of October 3, 2016. The listing does not specify an award ceiling or the expected number of awards in the provided source data, which suggests applicants would need to consult the full FOA text for budget expectations, project period limits, review criteria, and any institute-specific constraints.

Overall, the grant opportunity is best understood as a translational, industry-engaged NIAID program designed to push promising countermeasure candidates through key preclinical steps using a structured milestone framework, backed by a credible product development plan and tangible industry participation.

Browse more opportunities from the same agency: HHS-NIH11

Browse more opportunities from the same category: Health

Next opportunity: Revision Applications to U01 Awards for Research on the NCI's Provocative Questions (U01)

Previous opportunity: Grants to Prevent Prescription Drug/Opioid Overdose-Related Deaths (PDO)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA AI 16 034

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA AI 16 034) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 16 034", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.